Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/11457
Full metadata record
DC FieldValueLanguage
dc.rights.licenserestrictedAccess-
dc.contributor.authorMirjacic Martinović K.-
dc.contributor.authorVuletić A.-
dc.contributor.authorLj. Babović N.-
dc.contributor.authorDzodic, Radan-
dc.contributor.authorKonjević G.-
dc.contributor.authorJurisic, Vladimir-
dc.date.accessioned2021-04-20T18:24:27Z-
dc.date.available2021-04-20T18:24:27Z-
dc.date.issued2017-
dc.identifier.issn1043-4666-
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/11457-
dc.description.abstract© 2017 Elsevier Ltd Considering tumor-induced suppression of lymphocytes the aim of this study was to investigate in vitro effects of IFN-α, IL-2, IL-12 and IL-18 as immunomodulating agents on the functional and receptor characteristics of peripheral blood lymphocytes (PBL) in metastatic melanoma (MM) patients compared to healthy controls (HC). In HC IFN-α, IL-2 and IL-12 enhanced mRNA level of perforin by inducing pSTAT-1 and pSTAT-5 signaling molecules. Additionally, the expression of NKG2D activating receptor and its DAP10 signaling molecule was upregulated by IL-2. Contrary to this, in MM patients only IL-2 by upregulating pSTAT-5 increased perforin-mediated cytotoxicity of lymphocytes. Furthermore, there was significantly negative correlation between the percentage of CD4+CD25bright+CD27+ regulatory T (Treg) cells and NK cell cytotoxicity, as well as the expression of NKG2D receptor on PBL in HC and MM patients. Therefore, the absence of IL-2 effect on the increase of NKG2D/DAP10 level in MM patients could be the consequence of the increased percentage of immunosuppressive CD4+CD25bright+CD27+ cells after this cytokine treatment in patients. However, in MM IL-12 significantly decreases the percentage of these inhibitory cells. Although IL-2 as a single agent has numerous side effects, it remains the important cytokine for PBL activation in melanoma immunotherapy. Additionally, the removal of Treg cells from patient PBL by IL-12 before in vitro stimulation with IL-2, may lead to the generation of more potent cytotoxic lymphocytes against tumor cells. Therefore, lymphocyte based therapy for MM patients should integrate not only the choice of appropriate immunostimulatory cytokine, but also the removal of inhibitory cells from tumor microenvironment.-
dc.rightsinfo:eu-repo/semantics/restrictedAccess-
dc.sourceCytokine-
dc.titleAttenuated in vitro effects of IFN-α, IL-2 and IL-12 on functional and receptor characteristics of peripheral blood lymphocytes in metastatic melanoma patients-
dc.typearticle-
dc.identifier.doi10.1016/j.cyto.2017.02.024-
dc.identifier.scopus2-s2.0-85014723565-
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)

448

Downloads(s)

11

Files in This Item:
File Description SizeFormat 
PaperMissing.pdf
  Restricted Access
29.86 kBAdobe PDFThumbnail
View/Open


Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.